513.46
-1.44 (-0.28%)
| Penutupan Terdahulu | 514.90 |
| Buka | 520.00 |
| Jumlah Dagangan | 52,656 |
| Purata Dagangan (3B) | 372,749 |
| Modal Pasaran | 14,663,411,712 |
| Harga / Pendapatan (P/E TTM) | 33.58 |
| Harga / Pendapatan (P/E Ke hadapan) | 29.15 |
| Harga / Jualan (P/S) | 5.82 |
| Harga / Buku (P/B) | 30.82 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 22 Apr 2026 |
| Margin Keuntungan | 19.31% |
| Margin Operasi (TTM) | 20.32% |
| EPS Cair (TTM) | 13.10 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 9.30% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 11.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 25.33% |
| Nisbah Semasa (MRQ) | 0.730 |
| Aliran Tunai Operasi (OCF TTM) | 581.97 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 433.28 M |
| Pulangan Atas Aset (ROA TTM) | 15.44% |
| Pulangan Atas Ekuiti (ROE TTM) | 65.82% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Bercampur | Menaik |
| Diagnostics & Research (Global) | Bercampur | Menaik | |
| Stok | Medpace Holdings, Inc. | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | -3.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 1.25 |
|
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Mid Growth |
| % Dimiliki oleh Orang Dalam | 20.55% |
| % Dimiliki oleh Institusi | 91.47% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Mawer Investment Management Ltd. | 31 Dec 2025 | 407,302 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 560.00 (Jefferies, 9.06%) | Beli |
| Median | 511.00 (-0.48%) | |
| Rendah | 419.00 (TD Cowen, -18.40%) | Pegang |
| Purata | 504.17 (-1.81%) | |
| Jumlah | 2 Beli, 4 Pegang | |
| Harga Purata @ Panggilan | 443.01 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Barclays | 06 Mar 2026 | 500.00 (-2.62%) | Pegang | 470.59 |
| 11 Feb 2026 | 500.00 (-2.62%) | Jual | 423.93 | |
| RBC Capital | 03 Mar 2026 | 522.00 (1.66%) | Beli | 465.38 |
| TD Cowen | 18 Feb 2026 | 419.00 (-18.40%) | Pegang | 446.17 |
| Jefferies | 13 Feb 2026 | 560.00 (9.06%) | Beli | 428.03 |
| Leerink Partners | 11 Feb 2026 | 485.00 (-5.54%) | Pegang | 423.93 |
| Truist Securities | 11 Feb 2026 | 539.00 (4.97%) | Pegang | 423.93 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |